Increased fear- and stress-related anxiety-like behavior in mice lacking tuberoinfundibular peptide of 39 residues

Genes, Brain and Behavior

Volumn 7, Issue 8, 2008, Pages 933-942

  Fegley, D B ^a   Holmes, A ^b   Riordan, T ^a   Faber, C A ^a   Weiss, J R ^a   Ma, S ^a   Batkai, S ^b   Pacher, P ^b   Dobolyi, A ^c   Murphy, A ^d   Sleeman, M W ^d   Usdin, T B ^a,e  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d REGENERON PHARMACEUTICALS INC   (United States)

^e NONE   (United States)

Author keywords

Anxiety; Conditioned fear; Mouse knockout; Neuropeptide; Stress

Indexed keywords

NEUROPEPTIDE; PROTEIN TIP39; UNCLASSIFIED DRUG;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; CONDITIONING; CONTROLLED STUDY; FEAR; FREEZING; FRONTAL CORTEX; GENE DELETION; GENE MUTATION; HYPOTHALAMUS; ILLUMINATION; IMMOBILIZATION STRESS; KNOCKOUT MOUSE; MALE; MOUSE; NEUROMODULATION; NONHUMAN; NULL ALLELE; OPEN FIELD BEHAVIOR; PHENOTYPE; PRIORITY JOURNAL; PROVOCATION; REINFORCEMENT; SEPTUM PELLUCIDUM; STRIA TERMINALIS; WILD TYPE;

ANIMALS; ANXIETY DISORDERS; BRAIN CHEMISTRY; BRAIN STEM; DISEASE MODELS, ANIMAL; FEAR; GENETIC PREDISPOSITION TO DISEASE; LIMBIC SYSTEM; MALE; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEURAL PATHWAYS; NEUROPEPTIDES; STRESS, PSYCHOLOGICAL; THALAMUS;

MUS;

EID: 56749174972     PISSN: 16011848     EISSN: 1601183X     Source Type: Journal    
DOI: 10.1111/j.1601-183X.2008.00432.x     Document Type: Article

References (61)

1. Alonso, J., Angermeyer, M.C., Bernert, S. et al 2004) Use of mental health services in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand (Suppl 47 54.
2. Bale, T.L., Contarino, A., Smith, G.W., Chan, R., Gold, L.H., Sawchenko, P.E., Koob, G.F., Vale, W.W. Lee, K.F. (2000) Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat Genet 24, 410 414.
3. Bannon, A.W., Seda, J., Carmouche, M., Francis, J.M., Norman, M.H., Karbon, B. McCaleb, M.L. (2000) Behavioral characterization of neuropeptide Y knockout mice. Brain Res 868, 79 87.
4. Batkai, S., Pacher, P., Jarai, Z., Wagner, J.A. Kunos, G. (2004) Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors. Am J Physiol 287, H595 H600.
5. Belzung, C., Yalcin, I., Griebel, G., Surget, A. Leman, S. (2006) Neuropeptides in psychiatric diseases: an overview with a particular focus on depression and anxiety disorders. CNS Neurol Disord Drug Targets 5, 135 145.
6. Bignante, E.A., Rodriguez Manzanares, P.A., Mlewski, E.C., Bertotto, M.E., Bussolino, D.F., Paglini, G. Molina, V.A. (2008) Involvement of septal Cdk5 in the emergence of excessive anxiety induced by stress. Eur Neuropsychopharmacol 18, 578 588.
7. Boyce-Rustay, J.M. Holmes, A. (2005) Functional roles of NMDA receptor NR2A and NR2B subunits in the acute intoxicating effects of ethanol in mice. Synapse 56, 222 225.
8. Boyce-Rustay, J.M., Wiedholz, L.M., Millstein, R.A., Carroll, J., Murphy, D.L., Daws, L.C. Holmes, A. (2006) Ethanol-related behaviors in serotonin transporter knockout mice. Alcohol Clin Exp Res 30, 1957 1965.
9. Calvo, N., Martijena, I.D., Molina, V.A. Volosin, M. (1998) Metyrapone pretreatment prevents the behavioral and neurochemical sequelae induced by stress. Brain Res 800, 227 235.
10. Chotiwat, C. Harris, R.B. (2006) Increased anxiety-like behavior during the post-stress period in mice exposed to repeated restraint stress. Horm Behav 50, 489 495.
11. Coste, S.C., Kesterson, R.A., Heldwein, K.A., Stevens, S.L., Heard, A.D., Hollis, J.H., Murray, S.E., Hill, J.K., Pantely, G.A., Hohimer, A.R., Hatton, D.C., Phillips, T.J., Finn, D.A., Low, M.J., Rittenberg, M.B., Stenzel, P. Stenzel-Poore, M.P. (2000) Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. Nat Genet 24, 403 409.
12. Crawley, J.N. (1981) Neuropharmacologic specificity of a simple animal model for the behavioral actions of benzodiazepines. Pharmacol Biochem Behav 15, 695 699.
13. Cryan, J.F. Holmes, A. (2005) The ascent of mouse: advances in modelling human depression and anxiety. Nat Rev Drug Discov 4, 775 790.
14. Davis, M. Shi, C. (1999) The extended amygdala: are the central nucleus of the amygdala and the bed nucleus of the stria terminalis differentially involved in fear versus anxiety? Ann N Y Acad Sci 877, 281 291.
15. Dobolyi, A., Ueda, H., Uchida, H., Palkovits, M. Usdin, T.B. (2002) Anatomical and physiological evidence for involvement of tuberoinfundibular peptide of 39 residues in nociception. Proc Natl Acad Sci U S A 99, 1651 1656.
16. Dobolyi, A., Palkovits, M., Bodnar, I. Usdin, T.B. (2003a) Neurons containing tuberoinfundibular peptide of 39 residues project to limbic, endocrine, auditory and spinal areas in rat. Neuroscience 122, 1093 1105.
17. Dobolyi, A., Palkovits, M. Usdin, T.B. (2003b) Expression and distribution of tuberoinfundibular peptide of 39 residues in the rat central nervous system. J Comp Neurol 455, 547 566.
18. Dobolyi, A., Irwin, S., Wang, J. Usdin, T.B. (2006) The distribution and neurochemistry of the parathyroid hormone 2 receptor in the rat hypothalamus. Neurochem Res 31, 227 236.
19. Dunn, A.J. Swiergiel, A.H. (1999) Behavioral responses to stress are intact in CRF-deficient mice. Brain Res 845, 14 20.
20. Faber, C.A., Dobolyi, A., Sleeman, M. Usdin, T.B. (2007) Distribution of tuberoinfundibular peptide of 39 residues and its receptor, parathyroid hormone 2 receptor, in the mouse brain. J Comp Neurol 502, 563 583.
21. File, S.E. Wardill, A.G. (1975) Validity of head-dipping as a measure of exploration in a modified hole-board. Psychopharmacologia 44, 53 59.
22. Garcia, A.M., Cardenas, F.P. Morato, S. (2005) Effect of different illumination levels on rat behavior in the elevated plus-maze. Physiol Behav 85, 265 270.
23. Griebel, G. (1999) Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? Pharmacol Ther 82, 1 61.
24. Griebel, G., Moreau, J.L., Jenck, F., Martin, J.R. Misslin, R. (1993) Some critical determinants of the behaviour of rats in the elevated plus-maze. Behav Processes 29, 37 48.
25. Hariri, A.R. Holmes, A. (2006) Genetics of emotional regulation: the role of the serotonin transporter in neural function. Trends Cogn Sci 10, 182 191.
26. Hata, T., Nishikawa, H., Itoh, E. Funakami, Y. (2001) Anxiety-like behavior in elevated plus-maze tests in repeatedly cold-stressed mice. Jpn J Pharmacol 85, 189 196.
27. Heinrichs, S.C., Menzaghi, F., Pich, E.M., Baldwin, H.A., Rassnick, S., Britton, K.T. Koob, G.F. (1994) Anti-stress action of a corticotropin-releasing factor antagonist on behavioral reactivity to stressors of varying type and intensity. Neuropsychopharmacology 11, 179 186.
28. Heinrichs, S.C., Lapsansky, J., Lovenberg, T.W., De Souza, E.B. Chalmers, D.T. (1997) Corticotropin-releasing factor CRF1, but not CRF2, receptors mediate anxiogenic-like behavior. Regul Pept 71, 15 21.
29. Hogg, S. (1996) A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacol Biochem Behav 54, 21 30.
30. Hokfelt, T., Bartfai, T. Bloom, F. (2003) Neuropeptides: opportunities for drug discovery. Lancet Neurol 2, 463 472.
31. Holmes, A., Parmigiani, S., Ferrari, P.F., Palanza, P. Rodgers, R.J. (2000) Behavioral profile of wild mice in the elevated plus-maze test for anxiety. Physiol Behav 71, 509 516.
32. Holmes, A., Heilig, M., Rupniak, N.M., Steckler, T. Griebel, G. (2003) Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol Sci 24, 580 588.
33. Holmes, A., Li, Q., Koenig, E.A., Gold, E., Stephenson, D., Yang, R.J., Dreiling, J., Sullivan, T. Crawley, J.N. (2005) Phenotypic assessment of galanin overexpressing and galanin receptor R1 knockout mice in the tail suspension test for depression-related behavior. Psychopharmacology (Berl) 178, 276 285.
34. Hsu, H.R., Chen, T.Y., Chan, M.H. Chen, H.H. (2007) Acute effects of nicotine on restraint stress-induced anxiety-like behavior, c-Fos expression, and corticosterone release in mice. Eur J Pharmacol 566, 124 131.
35. Inui, A., Okita, M., Nakajima, M., Momose, K., Ueno, N., Teranishi, A., Miura, M., Hirosue, Y., Sano, K., Sato, M., Watanabe, M., Sakai, T., Watanabe, T., Ishida, K., Silver, J., Baba, S. Kasuga, M. (1998) Anxiety-like behavior in transgenic mice with brain expression of neuropeptide Y. Proc Assoc Am Physicians 110, 171 182.
36. Karlsson, R.M. Holmes, A. (2006) Galanin as a modulator of anxiety and depression and a therapeutic target for affective disease. Amino Acids 31, 231 239.
37. Kim, J.J., Fanselow, M.S., DeCola, J.P. Landeira-Fernandez, J. (1992) Selective impairment of long-term but not short-term conditional fear by the N-methyl-D-aspartate antagonist APV. Behav Neurosci 106, 591 596.
38. Kishimoto, T., Radulovic, J., Radulovic, M., Lin, C.R., Schrick, C., Hooshmand, F., Hermanson, O., Rosenfeld, M.G. Spiess, J. (2000) Deletion of crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2. Nat Genet 24, 415 419.
39. LaBuda, C.J., Dobolyi, A. Usdin, T.B. (2004) Tuberoinfundibular peptide of 39 residues produces anxiolytic and antidepressant actions. Neuroreport 15, 881 885.
40. LeDoux, J.E., Sakaguchi, A. Reis, D.J. (1984) Subcortical efferent projections of the medial geniculate nucleus mediate emotional responses conditioned to acoustic stimuli. J Neurosci 4, 683 698.
41. Lister, R.G. (1987) The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berl) 92, 180 185.
42. Martijena, I.D., Calvo, N., Volosin, M. Molina, V.A. (1997) Prior exposure to a brief restraint session facilitates the occurrence of fear in response to a conflict situation: behavioral and neurochemical correlates. Brain Res 752, 136 142.
43. Mechiel Korte, S. De Boer, S.F. (2003) A robust animal model of state anxiety: fear-potentiated behaviour in the elevated plus-maze. Eur J Pharmacol 463, 163 175.
44. Miyakawa, T., Yagi, T., Watanabe, S. Niki, H. (1994) Increased fearfulness of Fyn tyrosine kinase deficient mice. Behav Brain Res 27, 179 182.
45. Mukhopadhyay, P., Batkai, S., Rajesh, M., Czifra, N., Harvey-White, J., Hasko, G., Zsengeller, Z., Gerard, N.P., Liaudet, L., Kunos, G. Pacher, P. (2007) Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J Am Coll Cardiol 50, 528 536.
46. Otto, C., Martin, M., Wolfer, D.P., Lipp, H.P., Maldonado, R. Schutz, G. (2001) Altered emotional behavior in PACAP-type-I-receptor-deficient mice. Brain Res Mol Brain Res 92, 78 84.
47. Pacher, P., Liaudet, L., Bai, P., Mabley, J.G., Kaminski, P.M., Virag, L., Deb, A., Szabo, E., Ungvari, Z., Wolin, M.S., Groves, J.T. Szabo, C. (2003) Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation 107, 896 904.
48. Palmiter, R.D., Erickson, J.C., Hollopeter, G., Baraban, S.C. Schwartz, M.W. (1998) Life without neuropeptide Y. Recent Prog Horm Res 53, 163 199.
49. Rodgers, R.J., Cao, B.J., Dalvi, A. Holmes, A. (1997) Animal models of anxiety: an ethological perspective. Braz J Med Biol Res 30, 289 304.
50. Ross, G., Heinemann, M.P. Schlüter, K.D. (2007) Vasodilatory effect of tuberoinfundibular peptide (TIP39): requirement of receptor desensitizaion and its beneficial effect in the post-ischemic heart. Peptides 28, 878 886.
51. Schaefer, M.L., Wong, S.T., Wozniak, D.F., Muglia, L.M., Liauw, J.A., Zhuo, M., Nardi, A., Hartman, R.E., Vogt, S.K., Luedke, C.E., Storm, D.R. Muglia, L.J. (2000) Altered stress-induced anxiety in adenylyl cyclase type VIII-deficient mice. J Neurosci 20, 4809 4820.
52. Sluyter, F., Korte, S.M., Bohus, B. Van Oortmerssen, G.A. (1996) Behavioral stress response of genetically selected aggressive and nonaggressive wild house mice in the shock-probe/defensive burying test. Pharmacol Biochem Behav 54, 113 116.
53. Stein, D.J. Seedat, S. (2004) Unresolved questions about treatment-resistant anxiety disorders. CNS Spectr 9, 715.
54. Sugimura, Y., Murase, T., Ishizaki, S., Tachikawa, K., Arima, H., Miura, Y., Usdin, T.B. Oiso, Y. (2003) Centrally administered tuberoinfundibular peptide of 39 residues inhibits arginine vasopressin release in conscious rats. Endocrinology 144, 2791 2796.
55. Usdin, T.B., Bonner, T.I., Harta, G. Mezey, E. (1996) Distribution of parathyroid hormone-2 receptor messenger ribonucleic acid in rat. Endocrinology 137, 4285 4297.
56. Usdin, T.B., Hoare, S.R., Wang, T., Mezey, E. Kowalak, J.A. (1999) TIP39: a new neuropeptide and PTH2-receptor agonist from hypothalamus. Nat Neurosci 2, 941 943.
57. Usdin, T.B., Paciga, M., Riordan, T., Kuo, J., Parmelee, A., Petukova, G., Camerini-Otero, R.D. Mezey, E. (2008) Tuberoinfundibular peptide of 39 residues is required for germ cell development. Endocrinology 149, 4292 4300.
58. Valenzuela, D.M., Murphy, A.J., Frendewey, D. et al 2003) High-throughput engineering of the mouse genome coupled with high-resolution expression analysis. Nat Biotechnol 21, 652 659.
59. Wang, J., Palkovits, M., Usdin, T.B. Dobolyi, A. (2006) Afferent connections of the subparafascicular area in rat. Neuroscience 138, 197 220.
60. Ward, H.L., Small, C.J., Murphy, K.G., Kennedy, A.R., Ghatei, M.A. Bloom, S.R. (2001) The actions of tuberoinfundibular peptide on the hypothalamo-pituitary axes. Endocrinology 142, 3451 3456.
61. Wellman, C.L., Izquierdo, A., Garrett, J.E., Martin, K.P., Carroll, J., Millstein, R., Lesch, K.P., Murphy, D.L. Holmes, A. (2007) Impaired stress-coping and fear extinction and abnormal corticolimbic morphology in serotonin transporter knock-out mice. J Neurosci 27, 684 691.